Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Free Report) from a sell rating to a hold rating in a report issued on Sunday,Wall Street Zen reports.
A number of other brokerages have also recently commented on DMRA. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price target on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Guggenheim began coverage on Damora Therapeutics, Inc. Common Stock in a report on Friday. They issued a “buy” rating and a $59.00 price objective for the company. Jefferies Financial Group assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. Finally, TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a report on Monday, August 24th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $46.38.
Get Our Latest Report on Damora Therapeutics, Inc. Common Stock
Damora Therapeutics, Inc. Common Stock Stock Performance
Damora Therapeutics, Inc. Common Stock stock opened at $23.70 on Friday. The business’s 50 day simple moving average is $22.72 and its 200 day simple moving average is $25.70. Damora Therapeutics, Inc. Common Stock has a 12 month low of $4.95 and a 12 month high of $38.33. The company has a market cap of $1.47 billion, a price-to-earnings ratio of -7.03 and a beta of 1.52.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.12. As a group, equities research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Damora Therapeutics, Inc. Common Stock news, CEO Jennifer Jarrett bought 12,500 shares of the stock in a transaction on Friday, September 25th. The shares were acquired at an average price of $20.23 per share, with a total value of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at $10,367,875. The trade was a 2.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.40% of the company’s stock.
Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock
A number of large investors have recently made changes to their positions in the stock. Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the second quarter valued at $42,146,000. Seven Fleet Capital Management LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at $7,398,000. Squarepoint Ops LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $303,000. Finally, Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $260,000. 14.20% of the stock is owned by institutional investors.
More Damora Therapeutics, Inc. Common Stock News
Here are the key news stories impacting Damora Therapeutics, Inc. Common Stock this week:
- Positive Sentiment: Wall Street Zen raised its rating on DMRA to “Hold,” an improvement that may modestly bolster sentiment. Article: Damora Therapeutics Stock Bumped Up to Hold by Wall Street Zen
- Neutral Sentiment: Guggenheim initiated coverage, adding analyst attention; the headline does not specify its rating or price target. Article: Guggenheim Initiates Coverage on Damora Therapeutics
- Neutral Sentiment: DMRA crossed above its 50-day moving average, a potentially constructive technical signal, but the article also references an analyst downgrade. The downgrade’s details were not provided. Article: Damora Stock Crosses Above Fifty Day Moving Average After Analyst Downgrade
- Negative Sentiment: HC Wainwright lowered its 2026 and 2027 EPS forecasts, including its FY2027 estimate from a loss of $1.59 to $1.70 per share. It retained a “Buy” rating and $45 price target, tempering the negative read-through. MarketBeat coverage of Damora Therapeutics
About Damora Therapeutics, Inc. Common Stock
Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Further Reading
- Five stocks we like better than Damora Therapeutics, Inc. Common Stock
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
- After the Midterms, Which of These 3 Defense ETFs Looks Strongest?
- The Ugly Truth Behind SoundHound’s Q3 Results
Receive News & Ratings for Damora Therapeutics Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Damora Therapeutics Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
